

6.2 Caring for patient journeys, enhancing health outcomes

Patient Journey

PharmaEssentia contributes to health outcomes across various stages of the patient journey, including disease awareness and screening, MPN diagnosis confirmation and treatment, as well as comprehensive patient care post-treatment, providing holistic support.



Disease Awareness and Screening

PharmaEssentia not only continues to invest in ongoing professional education for healthcare professionals in the countries where its products are marketed but also supports healthcare professionals in conducting patient education events. Additionally, in accordance with local laws, online websites are established in the marketing countries such as:

- **WHAT'S NEXT PV:**

Serving as the main patient education website for the U.S. region, this platform helps the public understand disease-related knowledge and recognize disease risks. It aims to connect the patient community through the platform, providing comprehensive support for the body, mind, and spirit during treatment, and promoting smooth communication with medical professionals.

- **www.Besremi.com:**

Offers information for U.S. patients about medication use and treatment options.



Diagnosis and Treatment

In addition to being included in national and international treatment guidelines, PharmaEssentia conducts ongoing professional education for healthcare providers in the countries where its products are marketed. This is aimed at enhancing their understanding, diagnosis, treatment, and care of MPN. PharmaEssentia also collaborates with medical associations in the marketing countries and internationally to host seminars and continuously publish significant research findings.



In disease diagnosis and treatment, PharmaEssentia has organized numerous medical professional disease education events in global markets and published various research and development achievements in professional medical journals, enhancing breakthroughs in public health and healthcare outcomes.

Key Events for 2023:

- **2023 ASCO Annual Meeting:** Presentation of the EXCEED-ET study methodology.
- **2023 ASH Annual Meeting:** Presentation on the progress of research into Primary Myelofibrosis (PMF).
- **MPN Asia Annual Meeting:** Since 2016, PharmaEssentia has been a long-term sponsor of the MPN Asia Medical Annual Meeting, aiming to promote sustainable health and social inclusion. As of 2023, six editions have been successfully held, touring four cities in Asia, showcasing PharmaEssentia's innovative contributions and social impact in the field of rare MPN diseases, highly recognized by the external community.
- **Review by Japan's MHLW for Standard of Care (SOC):** Whether to include biomarker tracking in standard treatments to confirm the reduction in risk of deterioration and even the possibility of cure.
- **Collaboration and Academic Exchange with Associations in Taiwan:** Events with the Hematology Society of Taiwan, the Pharmacists Association, etc., to enhance physicians' knowledge of the MPN field and the effectiveness of long-acting interferon treatments.
- **Chiayi Chang Gung Memorial Hospital MPN Center:** PharmaEssentia and Chiayi Chang Gung Memorial Hospital have both been deeply involved in the MPN field for many years. In addition to promoting the importance of disease treatment through the center, they also conduct clinical research for genetic mutation testing to improve the accuracy of disease diagnosis and technology.
- **Education Training for Healthcare Providers in the USA:** The U.S. subsidiary provides sponsorships to Continuing Medical Education (CME) providers to offer more medical education, including medical conferences and on-demand educational content.



PharmaEssentia provides continuous and systematic education and training for healthcare professionals, as well as patient interaction events, to improve the overall care throughout the patient treatment journey. For example, in 2023, Panco hosted 17 seminars for healthcare professionals and patients to enhance understanding of diseases and medication treatment options, thereby enhancing professional medical knowledge. These events had a total of approximately 700+ participants.

Activity name	Target name	Purpose	Timeline (Short, Medium, Long Term)	Frequency	Benefits
MPN Asia	Healthcare Professionals	Increase understanding of the disease and medication treatment options	Long-term	Annually	Enhance professional medical knowledge
MPN Workshop	Healthcare Professionals	Increase understanding of the disease and medication treatment options	Long-term	Annually	Enhance professional medical knowledge
Patient Activities	Patients and Healthcare Professionals	Increase disease awareness	Medium-term	Quarterly	Enhance disease management knowledge
Regional Seminar	Healthcare Professionals	Increase understanding of the disease and medication treatment options	Medium-term	Quarterly	Enhance professional medical knowledge
Hospital Seminar	Healthcare Professionals	Increase understanding of the disease and medication treatment options	Short-term	Every two months	Enhance professional medical knowledge
Hematology Society Annual Conference Seminar	Healthcare Professionals	Increase understanding of the disease and medication treatment options	Long-term	Annually	Enhance professional medical knowledge

Comprehensive Patient Cycle Care

To assist in comprehensive cycle care for patients, PharmaEssentia has established patient support programs, actively supports patient education and case management, continues safety monitoring, helps reduce financial burdens for patients, and promotes complete treatment. In Taiwan, it has helped establish the [Taiwan Myeloproliferative Neoplasms Care Association \(TMPNA\)](#), and also supports the American Patient Power Foundation program and the MPN Research Foundation in the USA. Key outcomes include:

- Post-Marketing Safety Monitoring:**
PharmaEssentia continuously collects safety information for BESREMi® from all countries where it is marketed to update the Drug Safety Update Report (DSUR/PSUR) and assess the risk-benefit profile of BESREMi®. To date, there have been no incidents of non-compliance with product and service health and safety regulations.
- Establishment of the Taiwan Myeloproliferative Neoplasms Care Association (TMPNA):**
Enhances patient awareness of disease treatment.
- Establishment of MPN:**
Serves as a platform for MPN-related disease information in Taiwan, sharing new treatment knowledge and care recommendations.
- American Patient Power Foundation Program:**
Supports the treatment journey for PV patients and promotes correct treatment concepts through online digital programs, facilitating patient education, promoting doctor-patient dialogue, and enhancing public understanding.



- MPN Patient Group Assistance and International Educational Activities:**

Provides support for major North American patient-related group activities, including [MPN Research Foundation](#), [Canadian MPN Research Foundation](#), [MPN Advocacy & Education International](#), [Patient Power](#), and [PV Reporter](#). Offers online information sharing and physical events to enhance patient education and exchange of opinions, spread information about disease diagnosis, treatment goals, and disease progression, while also increasing the MPN community's understanding of the medical benefits of BESREMi.

- American MPN Research Foundation and Clinical Trial Search Engine:**

Helps establish a disease clinical trial search tool for MPNRF, providing a matching channel to assist MPN patients and their treating physicians in finding suitable clinical trials for subsequent treatment.



- Patient Case Management Support:**

- Taiwan Case Management Care:** Tracks patient treatment progress and subsequent medication reactions through a project-based approach.
- U.S. Medication Adherence Tracking:** If a patient discontinues medication due to adverse drug reactions, PharmaEssentia can receive discontinuation information through a specialty pharmacy database and accurately record it in the drug monitoring program for follow-up.

- Patient Support Plan:** (See detail in [6.2 Caring for patient journeys, enhancing health outcomes](#))

- Compassionate Use Program:** (See detail in [6.1 Access to Medicine Management](#))